WCLC 2023 | Outcomes of secondary analysis for RTOG 0617

Stephen Chun, MD, The University of Texas MD Anderson Cancer Centre, Houston, TX, shares the outcomes of a secondary analysis of a 5-year follow up on a Phase III trial (NCT00533949) of intensity-modulated radiotherapy for locally advanced non-small cell lung cancer (NSCLC). In comparison to 3D conformal radiotherapy, intensity-modulated technique demonstrated a significant reduction in severe pneumonitis. The secondary analysis also reported no associations between the low dose bath in intensity-modulated radiotherapy and overall survival, severe toxicity, or an increase in secondary malignancies. Dr Chun additionally suggests that age should not affect eligibility for chemoradiation as age was associated with survival in the analysis. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.